Public-registry site landscape for NCT04951622, a Myasthenia Gravis study sponsored by Janssen Research & Development, LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04951622 (registry record) |
| Sponsor | Janssen Research & Development, LLC |
| Condition(s) | Myasthenia Gravis |
| Phase | PHASE3 |
| Listed sites | 112 |
| Site countries | United States, Australia, Belgium, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Mexico |
At Neuromuscular Research Center and Clinic — one of the facilities listed on this trial — 1 other study is actively recruiting Myasthenia Gravis patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT04951622 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →